Home › Funds › RA CAPITAL MANAGEMENT, L.P. › FDMT
RA CAPITAL MANAGEMENT, L.P. position in FDMT
4D MOLECULAR THERAPEUTICS IN · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 5,049,779 shares of FDMT (4D MOLECULAR THERAPEUTICS IN) in its Q2 2026 13F filing — a position valued at US$67.2M, representing 0.58% of its reported portfolio and ranking #34 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s FDMT position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in FDMT in Q3 2023 at 4,163,211 shares (US$53.0M). The position peaked in Q1 2024 at 5,051,511 shares, worth US$160.9M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 5,049,779 shares valued at US$67.2M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.16M | $53.00M | New |
| Q4 2023 | 4.16M | $84.35M | Hold |
| Q1 2024 | 5.05M | $160.94M | Add |
| Q2 2024 | 5.10M | $107.01M | Add |
| Q3 2024 | 5.10M | $55.11M | Hold |
| Q4 2024 | 4.56M | $25.42M | Reduce |
| Q1 2025 | 4.56M | $14.74M | Hold |
| Q2 2025 | 4.56M | $16.93M | Hold |
| Q3 2025 | 4.56M | $39.65M | Hold |
| Q4 2025 | 5.65M | $42.40M | Add |
| Q1 2026 | 5.05M | $47.01M | Reduce |
| Q2 2026 | 5.05M | $67.16M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FDMT and 13F data
FDMT (4D MOLECULAR THERAPEUTICS IN) is a Health Care company. 35 other funds we track also report a position in FDMT — the largest reported positions include Novo Holdings A/S (US$43.2M), BVF INC/IL (US$38.3M), Trails Edge Capital Partners, LP (US$29.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FDMT
- Novo Holdings A/S 3.25M sh · $43.21M · Q2 2026
- BVF INC/IL 2.88M sh · $38.29M · Q2 2026
- Trails Edge Capital Partners, LP 2.23M sh · $29.63M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.00M sh · $26.60M · Q2 2026
- Evergreen Quality Fund GP, Ltd. 951.47K sh · $12.65M · Q2 2026
- Parkman Healthcare Partners LLC 948.18K sh · $12.61M · Q2 2026
- DIADEMA PARTNERS LP 571.11K sh · $7.60M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 507.80K sh · $6.75M · Q2 2026
- Catalio Capital Management, LP 471.25K sh · $6.27M · Q2 2026
- Opaleye Management Inc. 334.44K sh · $4.45M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held FDMT?
RA CAPITAL MANAGEMENT, L.P. has disclosed FDMT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in FDMT?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 5.05M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), valued at $67.16M, representing 0.58% of its reported portfolio and ranking #34.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling FDMT?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in FDMT. The position peaked in Q1 2024 at 5.05M shares.
Which other funds hold FDMT?
Other major institutional holders of FDMT include Novo Holdings A/S, BVF INC/IL, Trails Edge Capital Partners, LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.